Pharmaceuticals 2010, 3(10), 3258-3274; doi:10.3390/ph3103258

The Role of Monoclonal Antibodies in the Management of Leukemia

1 Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA 2 Department of Internal Medicine, Hematology Oncology section, Oklahoma University Health Sciences Center, 700 N.E. 13th Street, Oklahoma City, OK 74103, USA
* Author to whom correspondence should be addressed.
Received: 20 September 2010; Accepted: 18 October 2010 / Published: 18 October 2010
(This article belongs to the Special Issue Monoclonal Antibody)
PDF Full-text Download PDF Full-Text [133 KB, uploaded 18 October 2010 11:19 CEST]
Abstract: This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33. The introduction of rituximab, an anti CD20 monoclonal antibody, had a great impact in the treatment of lymphoproliferative disorders. Gemtuzumab, an anti CD 33 conjugated monoclonal antibody has activity in acute mylegenous leukemia (AML). As this field is undergoing a rapid growth, the years will see an increasing use of monoclonal antibodies in hematological malignancies.
Keywords: monoclonal Abs; leukemia; CLL; AML; ALL

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Al-Ameri, A.; Cherry, M.; Al-Kali, A.; Ferrajoli, A. The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals 2010, 3, 3258-3274.

AMA Style

Al-Ameri A, Cherry M, Al-Kali A, Ferrajoli A. The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals. 2010; 3(10):3258-3274.

Chicago/Turabian Style

Al-Ameri, Ali; Cherry, Mohamad; Al-Kali, Aref; Ferrajoli, Alessandra. 2010. "The Role of Monoclonal Antibodies in the Management of Leukemia." Pharmaceuticals 3, no. 10: 3258-3274.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert